#AlphaFold

The Light Switch Nobel: Why AI Just Turned Optogenetics Into a Startup Platform

Three scientists won the 2026 Medicine Nobel for optogenetics, but viral delivery, optics and human data still gate the five startup theses built around it.

Today in AI: Mathematics of AI Uncertainty

Google DeepMind's Zubin Ghahramani argues AI needs explicit Bayesian uncertainty, not just scale, to be trustworthy in the real world.

Demis Hassabis: Two Labs, Three Titles, and a $3.5B Drug Bet

Demis Hassabis now holds three formal roles inside Alphabet: Chairman of Google DeepMind, CEO of Isomorphic Labs, and the company's first Chief Scientist. StartupHub.ai data shows DeepMind employs 8,831 people with $1.33 billion in annual revenue, while Isomorphic Labs closed a $2.1 billion Series B in May 2026, carries a $3.5 billion valuation, and has $3 billion in combined pharmaceutical partnership ceilings with Eli Lilly and Novartis.

DeepMind's Game AI Evolves

Google DeepMind is advancing AI research through complex game environments, partnering with studios like Fenris Creations to develop general-purpose AI agents.

AI drug discovery: Biology, not just code

AI is not a magic wand for drug discovery; our limited understanding of human biology is the real bottleneck, not computational power.

Demis Hassabis Turns DeepMind Into Alphabet's $205B AI Engine

Google Cloud jumped 82 pct to $24.8 billion in Q2 2026, with DeepMind's Gemini models at the center. Here's how Demis Hassabis underpins Alphabet's $205 billion AI capex commitment and Isomorphic Labs's $2.1 billion drug discovery bet.

Google Pledges $40M for Genesis Mission AI

Google commits $40 million in AI resources to accelerate scientific discovery through the White House's Genesis Mission.

DeepMind's Bioresilience Play

Google DeepMind and Isomorphic Labs are leveraging AI for bioresilience, focusing on prevention, detection, and response to global health threats.

Demis Hassabis Says Google Leads AI Talent Race as Researchers Defect

Hassabis told Semafor on June 23 that Google DeepMind still wins the AI talent war, days after four researchers joined Anthropic. Here is what his dual mandate at Isomorphic Labs and Alphabet's $20B Google Cloud quarter mean for that claim.

Demis Hassabis's Isomorphic Labs: $2.7B Raised, Trials Due This Year

Isomorphic Labs raised $2.7B total through May 2026. How the pharma deals with Lilly and Novartis work, what IsoDDE changed, and when trials begin.

Architectural Interactivity, Linguistic Interpretability, and Molecular Synthesis: The Frontier of Native AI

Three organisations now define the frontier of native AI: Thinking Machines is rebuilding human-AI collaboration as a low-latency interaction model, the Effable movement wants interpretable safety frameworks like SafetyAnalyst, and Isomorphic Labs is converting AlphaFold into an end-to-end drug design engine. The common thread is moving from AI as a layer of abstraction toward AI as a fundamental component of human and biological systems.

Demis Hassabis in 2026: How DeepMind Is Turning AlphaFold Into a Drug Discovery Engine

Demis Hassabis has spent 2026 arguing that AlphaFold is the first rung in an AI-powered scientific revolution. Here is how his thesis maps to Isomorphic Labs' drug pipeline, DeepMind's research agenda, and his view that the generative AI boom may paradoxically slow deeper progress.

Google DeepMind Taps South Korea for AI Science

Google DeepMind partners with South Korea's Ministry of Science and ICT to accelerate scientific discovery using advanced AI, establishing an AI Campus in Seoul.

AI Designs Dog's Cancer Vaccine

An AI expert engineered a personalized mRNA cancer vaccine for his dying dog, Rosie, using advanced AI tools, resulting in significant tumor reduction.

AlphaFold Powers Engineering of Resilient Crops

AlphaFold Protein Prediction Reshapes APAC Research